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Background: Expert consensus statements on management of implantable cardioverter deﬁbrillators (ICDs) em-
phasize the importance of having discussions about deactivation before and after implantation. These statements
were developedwith limited patient input. The purpose of this studywas to identify the factors associatedwith pa-
tients' experiences of end-of-life discussions, attitudes towards such discussions, and attitudes towardswithdrawal
of therapy (i.e., generator replacement and deactivation) at end-of-life, in a large national cohort of ICD-recipients.
Methods:We enrolled 3067 ICD-patients, administrating the End-of-Life-ICD-Questionnaire.
Results:Most (86%) had not discussed ICD-deactivation with their physician. Most (69%) thought discussions were
best at end-of-life, but 40% stated that they never wanted the physician to initiate a discussion. Those unwilling to
discuss deactivation were younger, had experienced battery replacement, had a longer time since implantation,
and had better quality-of-life. Thosewith psychologicalmorbidityweremore likely to desire a discussion about de-
activation. Many patients (39%) were unable to foresee what to decide about deactivation in an anticipated termi-
nal condition. Women, those without depression, and those with worse ICD-related experiences were more
indecisive about withdrawal of therapy. Irrespective of shock experiences, those who could take a stand regarding
deactivation chose to keep shock therapies active in many cases (39%).
Conclusions: Despite consensus statements recommending discussions about ICD-deactivation at the end-of-life,
such discussion usually do not occur. There is substantial ambivalence and indecisiveness on the part of most
ICD-patients in this nationwide survey about having these discussions and about expressing desires about deacti-
vation in an anticipated end-of-life situation.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.1. Introduction
Recent expert consensus statements from the Heart Rhythm Society
[1] and the European Heart Rhythm Association [2] have emphasized
the importance of discussing the issue of deactivation toward the end-
of-life with implantable cardioverter deﬁbrillator (ICD) recipients, and
initiating such discussions before ICD implantation. Communicationts from the Medical Research
and Lung Association, Magnus
(ViC), The Swedish Society of
rsity Hospital Research Fund.
, Linköping University Hospital,
+46 10 103 22 24.
eliability and freedom frombias
land Ltd.Open access under CC BY-NCabout ICDs at the end-of-life presents many challenges, and it is unclear
if clinicians and patients routinely discuss management of ICDs at the
end-of-life and the alternative modes of dying [3,4]. In several small
scale studies, investigators have examined patient preferences for dis-
cussions regarding death and attitudes about deactivation of ICDs at
the end-of-life [5–14]. The majority of patients want to be involved in
a deactivation discussion [6,11], yet some are reluctant [7,8,14] and
also uncomfortable discussing advanced directives with their families
[13]. Some investigators have found that ICD recipients want to have
an end-of-life discussion sooner rather than later in the illness trajectory
[12], preferably prior to implantation [11]. Others reported that patients
prefer such discussion be held when it is suspected that their life expec-
tancy is decreased [6,7]. Patients have reportedmixed preferences about
keeping their device activated at the end-of-life. Some investigators
have provided patients with hypothetical scenarios and found that the
majority of patients prefer to keep the ICD active if they had a serious
illness and were unlikely to survive [5,7,10], even if it meant receiving
multiple shocks at end-of-life [10]. Others have found that most ICD pa-
tients favor device deactivation at end-of-life [6,9]. A recent systematic
review by Russo (2011) concluded thatmore research regarding patient-SA license.
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lacking about when ambulatory patients prefer to receive information
and engage in discussions about ICD deactivation at the end-of-life.
The purpose of this nationwide cross-sectional study was to
identify the factors associated with patients' experiences of end-of-life
discussions, attitudes towards such end-of-life discussions, and atti-
tudes towards withdrawal of therapy (i.e., generator replacement and
deactivation) at end-of-life in a large national cohort of ICD recipients
independently of psychological distress and quality-of-life. Speciﬁc
aims were to 1) describe ICD patients' experiences of end-of-life
discussions – and attitudes towards – such end-of-life discussions
and ICD therapy at end-of-life; 2) determine the association of socio-
demographic and clinical variables (i.e., gender, age, education, ICD
indication, time since implantation, type of ICD, shock experience, and
prior ICD battery replacement) controlling for anxiety symptoms, de-
pressive symptoms and quality-of-life (QOL),with patient's experiences
of end-of-life discussions; and 3) determine the association of these
same variables with patient's attitudes towards end-of-life discussions
and withdrawal of therapy at end-of-life.
2. Methods
2.1. Study Design, Sample and Data Collection
This was a cross-sectional, correlational study in which self-reported data was used.
The study conforms to the Declaration of Helsinki and was approved by the Regional
Ethics Committee for Human Research at the University of Linköping, Sweden. Patients
were recruited from the Swedish ICD- and Pacemaker registry; a national quality database
in which all recipients of cardiovascular implantable electronic devices in Sweden have
been registered since the start in 1989. All adult patients eligible in the registry in 2011
(n = 5535) were sent an invitation to participate in the study during September to Octo-
ber 2012. After completing an informed consent explaining that the study was voluntary
and that they could withdraw from the study at any time, the patients were mailed the
questionnaire. One reminder was sent out 3–4 weeks following the ﬁrst letter.
2.2. Measures and Instruments
2.2.1. Demographic and clinical variables
Socio-demographic variables collected included gender, age, marital status, and edu-
cational level. Information on clinical variables, including indication for ICD implantation,
cardiac resynchronization therapy, battery replacement, and time since implantationwere
obtained from the Swedish ICD- and Pacemaker registry. Information on co-morbidities
was self-reported. Satisfaction with the ICD, and experience of shocks was obtained
through investigator-designed questions.
2.2.2. End-of-life concerns
Data on end-of-life perceptions and attitudes was collected using the “Experiences,
Attitudes and Knowledge of End-of-Life Issues in Implantable Cardioverter Deﬁbrillator
Patients (EOL-ICD) Questionnaire”. The instrument is a self-rated questionnaire contain-
ing three domains that measure experiences (10 items), attitudes (18 items) and knowl-
edge (11 items) of end-of-life in ICD patients. The EOL-ICD Questionnaire was originally
developed and tested for content and construct validity and for homogeneity and reliabil-
ity in a Swedish setting. The validity, as well as the reliability, properties were considered
sufﬁcient [16].
Respondents list their answer as “yes/no” or “no opinion”, “agree/don't agree”, “true/
false”, or “don't know”. The experiences domain includes items about patients' actual dis-
cussion experiences. Example items in the experiences domain are “I have discussed
what a battery replacement involves with my ICD doctor or nurse”, and “I have told my
next of kin (either in writing or orally) my wishes regarding the deﬁbrillator shocks in
my ICD, if I become seriously ill with some fatal disease”. The attitudes domain includes
items about patients' attitudes towards potential future discussions and future events. Ex-
amples of items on the attitudes domain are “I do not wish to have a conversation about
turning off deﬁbrillating shocks withmy doctor”, “I want to have the battery inmy ICD re-
placed even if I am seriously ill suffering from another disease”, and “I want to have the
deﬁbrillating shocks in my ICD even if dying of cancer or another serious disease”. The
knowledge domain involves questions such as “Turning off the deﬁbrillating shocks in an
ICD is the same as active euthanasia”, and “An ICD always gives deﬁbrillating shocks in
connection with end-of-life”. In this paper we are reporting results from the experiences
and attitudes domains only.
2.2.3. Psychological measures and quality-of-life
Given the possibility that psychological distress might inﬂuence patients' experiences
and attitudes toward end-of-life concerns, questionnaires assessing QOL, anxiety symp-
toms, and depressive symptomswere also included in the survey. Quality-of-lifewasmea-
sured using the EuroQol-5D [17], an instrument with well-established reliability and
validity. Anxiety and depression symptoms were assessed using the 8-item HospitalAnxiety and Depression Scale (HADS) [18], which has been used extensively in the evalu-
ation of anxiety and depression symptoms in both hospitalized and non-hospitalized
patients.
2.3. Statistical analysis
Data were analyzed with SPSS software, version 21.0 (SPSS, Chicago, Illinois). Proba-
bility values of p b .05 were considered signiﬁcant. Comparisons between study partici-
pants and non-participants on background characteristics were performed using the
Chi-square test for nominal variables (e.g., gender, ICD indication) and two-tailed
Student's t-test for independent samples for continuous variables (e.g., age, time since im-
plantation). Simple frequencies and proportionswere used to describe the patient sample,
frequency and timing of occurrence of discussions about ICD deactivation, and attitudes
about battery replacement and deactivation.
A series of logistic regression models was used to determine the association of
sociodemographic and clinical variables (i.e., gender, age, education, ICD indication, time
since implantation, type of ICD (CRT-D versus ICD), shock experience, and prior ICD bat-
tery replacement) controlling for anxiety symptoms, depressive symptoms and QOL,
with patient's experiences of, and attitudes towards, end-of-life discussions and with-
drawal of therapy at end-of-life. In these models we determined predictors of a “yes” or
“no” answer to each question about experiences of end-of-life discussions, and attitudes
towards end-of-life discussions and withdrawal of therapy at the end-of-life. Each of the
predictor variables were forced into the model in order to provide simultaneous control
for all variables.
Chi-square tests were used to determine bivariate association of socio-demographic,
clinical, and psychological measures with (1) attitudes on elective generator replacement
at end-of-service indicator; (2) attitudes on deactivation at end-of-life, and (3) attitudes
about maintaining ICD therapy in the context of terminal illness. For the Chi-square
tests, post-hoc examination of the standardized residuals that exceeded the critical
value associated with p b .05 was used to determine which cell or cells contributed to
the signiﬁcant difference.
Multinomial logistic regression was used to determine predictors of the response to
the item asking for patients' attitudes regarding the item, “I want to have the deﬁbrillating
shocks in my ICD even if dying of cancer or other serious disease”. Because this item has
three potential responses (i.e., yes, no, or can't take a stand), multinomial versus logistic
regression was used.
Finally, given the ﬁnding that a large percentage of respondents were indecisive with
regard to ability to make a decision about withdrawal of therapy and deactivation under
speciﬁc circumstances, we conducted an additional analysis using linear regression to de-
termine predictors of indecisiveness. The dependent variable was created by averaging
scores of ﬁve items from the attitude domain. These items focused on ability to come to
adecision about battery replacement under the circumstances of havingnot received shocks,
being seriously ill and having reached an advanced age, plus two questions about choosing
to keep the ICD active even if dying from cancer or other serious illness, or if receiving shocks
daily. Predictors included in the regression analysis involved background characteristics,
clinical characteristics, and psychological measures. Predictors were forced into the model
to provide simultaneous control of all variables.
3. Results
Of the 5535 patients approached, 1502 did not respond, 700 patients
declined to participate, 96 chose to withdraw from the study, and 170
did not return the questionnaire despite one reminder. A total of 3067
patients completed the survey (55% response rate). No statistically
signiﬁcant differences were found in background characteristics in
terms of age, gender, time since implantation, or ICD indication between
participants and non-participants.
3.1. Background Characteristics
Sample characteristics are presented in Table 1. Themean age of the
sample was 66 years with a range of ages enrolled from 19 to 94 years,
and 80% were male. Time since implantation ranged from one to
23 years with a mean of 4.7 years, 23% had a CRT-D implanted and
25% had previously undergone an elective battery replacement. The
majority (64%) had received their ICD as a secondary prevention
treatment, while the remainder had received their ICD for primary pre-
vention, usually in the context of heart failure.
The vast majority (96%) of patients rated their general experience as
an ICD recipient as “very”, or “rather good” compared to only 4% who
rated it “rather” or “very bad”. Sixteen percent of patients stated that
they had religious faith or a religious outlook on life that helped them
manage life as an ICD recipient. A total of 35% of patients had experi-
enced one or more deﬁbrillating shocks. In connection with the latest
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(4.6 and 4.5, respectively), when rated on a visual analog scale (where
0 means no pain/anxiety and 10 the worst possible pain/anxiety
imaginable). Of the sample, only 4% had, at some point, considered
deactivation of their ICD.
3.2. Experiences and Attitudes towardWithdrawal-of-Therapy-Discussions
Only 43% of patients had at some time discussedwhat a forthcoming
battery replacement would involve with their physician, and 32% had
discussed the topic with a family member. Among the predictors
entered into themodel, QoL, age, time since implantation, and prior bat-
tery replacement independently predicted whether patients had had
such a discussion (Table 2). Patients with better QoL, those younger
than 65, those who had the ICD implanted for a longer period of time,
and those who had a prior battery replacement were more likely to
have discussed battery replacement with their clinician. With regard
to predictors of having such a discussion with their family members,
again, patients with better QoL, those younger than 65, those with the
ICD for a longer period of time, and those who had a prior battery re-
placement were more likely to have discussed battery replacement
with their next-of-kin (Table 2).
The vast majority (86%) had not had a discussionwith their clinician
aboutwhat ICD deactivation and turning off deﬁbrillating shocks would
involve. Logistic regression demonstrated that anxious patients, youn-
ger patients, and those who had received ICD shocks and prior battery
replacement were more likely to have had such a discussion (Table 2).
Just one-tenth of patients had discussed the implications of ICD deacti-
vation with their family members. Independent predictors of this dis-
cussion with family members were presence of anxiety symptoms,
having received prior deﬁbrillating shocks or prior battery replacement
(Table 2). Only 7% had told their familymembers of their wishes for ICD
deactivation if they become seriously ill with a fatal disease. Only female
gender or prior battery replacement were independent predictors
of having this discussion (Table 2). A minority (37%) stated they hadTable 1
Demographic and clinical characteristics, N = 3067.
Characteristic Value a
Demographics
Age (years) 65.9 (11.5)
Gender (male) 2438 (79.5%)
Education (lower) b 1009 (33.2%)
Clinical factors
Time since implantation (years) 4.7 (3.9)
ICD-indication (primary prevention) 1109 (36.2%)
Resynchronization therapy (CRT-D, yes) 717 (23.4%)
Shock experience (yes) 1056 (34.9%)
Generator replacement (yes) 774 (25.2%)
Co-morbidity c
Myocardial infarction 1037 (33.8%)
Atrial ﬁbrillation 1280 (41.8%)
Heart failure 1606 (52.4%)
Chronic obstructive pulmonary disease 448 (14.6%)
Diabetes mellitus 612 (20.0%)
Stroke 272 (8.9%)
Cancer 202 (6.6%)
Psychological measures d
Quality-of-life index, mean .818 (.211)
Quality-of-life, visual analog scale 72.8 (18.2)
Anxiety 485 (16.1%)
Depression 263 (8.7%)
a Data are presented as mean + SD or n (%).
b Compulsory secondary school, with a total education time b 9 years.
c Self-reported by subjects.
d Psychological measures: QOL was assessed with EQ-5D (mean index score and visual
analog score-VAS; a higher score indicated a better QOL), anxiety and depression with
HADS (categorical with a cut-offs ≥8 indicating anxiety/depression).discussed with their physician their underlying illness and what to ex-
pect for the illness trajectory in the future. Variables that independently
predicted engagement in such a discussion were male gender, age
younger than 65, history of deﬁbrillating shocks, higher levels of educa-
tion, and having an ICD versus a CRT-D implanted (Table 2). A similar
minority (37%) had discussed their heart disease and its progression
with their family members. Independent predictors of having such a
discussion were age younger than 65, history of deﬁbrillating shocks,
higher levels of education, and having an ICD versus a CRT-D implanted
(Table 2).
3.3. Timing of Discussions about ICD Deactivation
With regard to attitudes about discussion surrounding ICD deactiva-
tion in an anticipated end-of-life situation, 40% of patients stated that
they never wanted the physician to initiate a discussion, while 84%
stated they wanted to broach the question about deactivation when
they felt it was needed. Most patients (69%) stated that they preferred
discussing what is involved with ICD deactivation during the last days
in life, yet 50% also said they would like the discussion to be held in
connection with the ICD implantation. Overall, most people would
prefer these discussions be held when their health deteriorates, rather
than routinely (Table 3).
We determined predictors of the attitude of never wanting the
physician to discuss ICD deactivation. Based on logistic regression,
the patients who did not want to discuss ICD deactivation were
more likely to be younger and without symptoms of anxiety. In addi-
tion, these patients were more likely to have received prior ICD
shocks (Table 4).
3.4. Attitudes towardWithdrawal of Therapy at the Battery-End-of-Service
Themajority of patients stated that even if no shock therapy had been
delivered (79%) they would like to replace the ICD battery when it has
reached the end-of-service indicator, while 16% could not take a stand
on this item, and 5% would not want to replace the ICD battery in this
circumstance. The prevalence of these attitudes by various socio-
demographic, implantation, psychological and end-of-life discussion ex-
periences are indicated in Table 5. From bivariate analyses, there were
no differences in the prevalence of these attitudes based on gender,
whether the ICD was inserted for primary or secondary prevention, type
of ICD (i.e., CRT-D or ICD), receipt of prior shocks, symptoms of anxiety,
or prior discussionswith the ICD teamabout deactivation. Therewere sig-
niﬁcant differences based on age, education, time since ICD implantation,
prior battery replacement, having had discussions with the ICD team
about battery replacement and about illness trajectory. Speciﬁcally,
patients who were younger, those with lower levels of education, and
those with depressive symptoms were more likely to state that they did
not want the battery replaced even if no shocks had been delivered. Sig-
niﬁcantly more patients who had their ICD for 5 or fewer years were un-
able to take a stand than those who had their ICD for longer than 5 years.
Patientswhohad a prior battery replacementwere less likely to state they
could not take a stand regarding battery replacement if no shocks had
been delivered. Patients who had any prior discussion with the ICD
team about battery replacement were less likely to be unable to take a
stand as were those who had a prior discussion about illness trajectory.
Themajority of patients also reportedwanting to replace the battery
even when they reached a very advanced age (63%), while 27%
could not take a stand, and 10% did not want the battery replaced in
this circumstance. The prevalence of these attitudes by various socio-
demographic, implantation, psychological and end-of-life discussion
experiences are indicated in Table 6. Younger patients more commonly
said they did not want the battery replaced even at an advanced
age, and men more commonly said they did want it replaced than
did women, although women more commonly than men were unable
to take a stand. Those who had no prior discussion about battery
Table 2
Logistic regression results for experiences of, and attitudes towards, withdrawal-of-ICD-therapy-discussions, N = 3067.
B P value Odds ratio 95% CI
Discussed what battery replacement involves with ICD physician or nurse, Omnibus p value b .001
Symptoms of depression −.311 .086 .733 .513–1.046
Symptoms of anxiety .086 .534 1.089 .832–1.427
Quality-of-life score .480 .045 1.615 1.010–2.584
Male .071 .511 1.074 .869–1.327
Age b 65 years (vs. ≥65 years) .299 b .001 1.349 1.123–1.620
≤9 years of education (vs. N9 years) −.086 .361 .918 .764–1.103
Time since implantation of ICD, years .122 b .001 1.130 1.090–1.173
CRT-D (vs. ICD only) .065 .547 1.067 .864–1.317
Secondary prevention (vs. primary) .129 .187 1.137 .939–1.377
Received ICD shocks .055 .567 1.057 .874–1.278
Had prior generator replacement 1.558 b .001 4.739 3.565–6.298
Discussed what battery replacement involves with family, Omnibus p value b .001
Symptoms of depression −.248 .183 .781 .543–1.123
Symptoms of anxiety .125 .375 1.133 .860–1.492
Quality-of-life score .511 .039 1.667 1.027–2.707
Male .179 .098 1.196 .968–1.477
Age b 65 years (vs. ≥65 years) .325 .001 1.384 1.149–1.667
≤ 9 years of education (vs. N9 years) .026 .787 1.026 .850–1.239
Time since implantation of ICD, years .110 b .001 1.117 1.080–1.155
CRT-D (vs. ICD only) .151 .172 1.163 .936–1.445
Secondary prevention (vs. primary) .152 .140 1.165 .951–1.426
Received ICD shocks −.060 .545 .942 .776–1.143
Had prior generator replacement 1.169 b .001 3.219 2.479–4.180
Discussed with ICD physician or nurse what turning off deﬁbrillating shocks involves, Omnibus p value b .001
Symptoms of depression −.079 .708 .924 .613–1.393
Symptoms of anxiety .494 .002 1.638 1.198–2.239
Quality-of-life score −.186 .518 .830 .472–1.460
Male −.034 .804 .967 .741–1.262
Age b 65 years (vs. ≥65 years) .311 .008 1.364 1.084–1.717
≤9 years of education (vs. N9 years) .123 .306 1.131 .894–1.430
Time since implantation of ICD, years .014 .476 1.014 .976–1.052
CRT-D (vs. ICD only) .014 .922 1.014 .770–1.335
Secondary prevention (vs. primary) −.042 .752 .959 .739–1.244
Received ICD shocks .585 b .001 1.795 1.422–2.265
Had prior generator replacement .735 b .000 2.086 1.504–2.893
Discussed with family what turning off deﬁbrillating shocks involves, Omnibus p value b .001
Symptoms of depression .013 .955 1.013 .654–1.569
Symptoms of anxiety .582 .001 1.789 1.279–2.503
Quality-of-life score −.294 .342 .746 .407–1.366
Male .201 .167 1.223 .920–1.626
Age b 65 years (vs. ≥65 years) .142 .281 1.152 .890–1.491
≤9 years of education (vs. N9 years) .152 .250 1.165 .899–1.509
Time since implantation of ICD, years .017 .417 1.017 .976–1.061
CRT-D (vs. ICD only) −.105 .508 .900 .660–1.229
Secondary prevention (vs. primary) −.059 .689 .943 .706–1.258
Received ICD shocks .511 b .001 1.667 1.285–2.163
Had prior generator replacement .505 .007 1.658 1.147–2.396
Discussed with family wishes if seriously ill with fatal disease, Omnibus p value b .001
Symptoms of depression .068 .808 1.070 .621–1.842
Symptoms of anxiety .139 .531 1.149 .744–1.773
Quality-of-life score −.683 .058 .505 .249–1.024
Male .359 .036 1.432 1.024–2.003
Age b 65 years (vs. ≥65 years) .114 .479 1.121 .818–1.536
≤9 years of education (vs. N9 years) .069 .672 1.071 .779–1.475
Time since implantation of ICD, years −.009 .750 .991 .941–1.045
CRT-D (vs. ICD only) .106 .564 1.112 .776–1.592
Secondary prevention (vs. primary) −.142 .422 .867 .613–1.227
Received ICD shocks .158 .341 1.171 .846–1.622
Had prior generator replacement .705 .002 2.023 1.288–3.179
Discussed illness trajectory with ICD physician or nurse, Omnibus p value b .001
Symptoms of depression −.221 .183 .802 .579–1.110
Symptoms of anxiety .055 .666 1.057 .823–1.357
Quality-of-life score −.272 .209 .762 .499–1.165
Male −.377 b .001 .686 .561–.838
Age b 65 years (vs. ≥65 years) .461 b .001 1.585 1.340–1.876
≤9 years of education (vs. N9 years) −.443 b .001 .642 .539–.764
Time since implantation of ICD, years .011 .458 1.012 .981–1.043
CRT-D (vs. ICD only) .387 b .001 1.472 1.212–1.787
Secondary prevention (vs. primary) −.080 .386 .923 .770–1.107
Received ICD shocks .465 b .001 1.592 1.337–1.896
(continued on next page)
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Table 2 (continued)
B P value Odds ratio 95% CI
Had prior generator replacement .259 .052 1.295 .997–1.682
Discussed heart disease development with family, Omnibus p value b .001
Symptoms of depression .065 .686 1.067 .779–1.460
Symptoms of anxiety .068 .587 1.070 .837–1.368
Quality-of-life score −.203 .341 .816 .538–1.239
Male −.039 .690 .962 .793–1.166
Age b 65 years (vs. ≥65 years) .359 b .001 1.432 1.213–1.690
≤9 years of education (vs. N9 years) −.296 .001 .743 .627–.882
Time since implantation of ICD, years .004 .777 1.004 .975–1.035
CRT-D (vs. ICD only) .347 b .001 1.415 1.170–1.712
Secondary prevention (vs. primary) −.171 .059 .843 .705–1.007
Received ICD shocks .255 .004 1.291 1.085–1.535
Had prior generator replacement .169 .202 1.284 .913–1.534
Legend: CI = Conﬁdence Intervals; CRT-D = Cardiac Resynchronization Therapy-Deﬁbrillator; ICD = Implantable Cardioverter Deﬁbrillator.
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while those who had a prior discussion more commonly said they
wanted battery replacement even at an advanced age. There were no
differences in attitudes based on education level, ICD indication, ICD
type, time since implantation, prior shock experience, prior generator
replacement, presence of symptoms of anxiety or depression, or prior
discussions about illness trajectory or ICD deactivation.
A majority of patients (55%) desired battery replacement even
if seriously ill, while 34% were unable to take a stand on this issue,
and 11% said no. The prevalence of these attitudes by various socio-
demographic, implantation, psychological and end-of-life discussion
experiences are indicated in Table 7. Women either more commonly
said they could not take a stand or said no to this issue, those with
a CRT-D less commonly said no, and those who had discussed deactiva-
tionwith their ICD teammore commonly said no. There were no differ-
ences in attitudes based on age, education level, ICD indication, time
since implantation, prior shock experience, prior generator replace-
ment, presence of symptoms of anxiety or depression, or prior discus-
sions about illness trajectory or battery replacement.
3.5. Attitudes toward ICD Deactivation at End-of-Life
More patients “could not take a stand (39%) about whether they
would like to have the ICD deactivated if a terminal illness developed”
than said “yes (22%), they would like it deactivated” or “no (39%),
they do not want it deactivated even if a terminal illness like cancer de-
veloped”. There were no differences in the prevalence of these attitudes
based on age, education level, ICD indication, time since implantation,
receipt of previous shocks, symptoms of anxiety, depressive symptoms,
having had a prior discussion with the physician about battery replace-
ment, or having had a prior discussion with the physician about illnessTable 3
Attitudes about preferable situations in which to discuss what ICD deactivation involves,
N = 3067.
Speciﬁc situation Value a
I don't wish to have such a conversation 1204 (40.0)
I myself will broach the question when I feel the need to 2529 (84.3)
In connection with the ICD surgery 1466 (49.6)
If I receive a shock 1502 (50.5)
If I have repeated shocks 1938 (65.2)
Upon repeatedly being hospitalized due to recurring heart problems 1870 (63.0)
If I should suffer from a disease with a poor prognosis (e.g., cancer) 1932 (64.6)
Routinely upon return visits to the ICD clinic 1249 (41.7)
If my heart disease, which is the reason for the ICD treatment,
deteriorates
1935 (64.8)
Towards end-of-life, during the last days 2043 (69.1)
a Data are presented as number and percentages, with proportions of patients agreeing
to each statement. Patients were asked to take a stand for each statement.trajectory (Table 8). There were differences based on gender, type of
ICD, prior battery replacement, and prior discussionswith the physician
about deactivation. Speciﬁcally, womenwere less likely to say “yes, they
would like to have the ICD deactivated if a terminal illness developed”,
as were those with prior battery replacement. Those with a CRT-D
were more likely to say “yes”, and those who had a prior discussion
with their physician about deactivation were less likely to say they
often “could not take a stand” (Table 8). Multinomial logistic regression
revealed that only gender, having had a prior discussion about ICD deac-
tivation with the physician, and CRT-D therapy predicted this attitude.
Compared to patients who stated “no” to the item asking if they
would like to have the ICD deactivated if a terminal illness developed,
those who said “yes” were more likely to be men (Odds ratio 1.79,
95% conﬁdence intervals (CI) 1.36–2.34, p b .001) and more likely to
have a CRT-D versus ICD implanted (Odds ratio 1.35, 95% CI 1.06–1.73,
p = .017). No other covariates entered into the model.3.6. Predictors of indecisiveness
Given our unexpected ﬁndings of a large number of patients who
were indecisive (i.e., unable to take a stand) about a number of end-
of-life issues related to their ICD, we conducted a secondary analysis
to further explore this phenomenon. We used linear regression in
order to determine predictors of indecisiveness from the following var-
iables: gender; age; education level; type of ICD; ICD indication; time
since implantation; history of myocardial infarction, heart failure or
cancer; quality-of-life score; depressive symptoms; anxiety symptoms;
prior discussions with the ICD team about battery replacement and ICD
deactivation; general experiences with the ICD; prior ICD shocks; anxi-
ety related to ICD shocks; and pain related to ICD shocks. The overallTable 4
Logistic regression for attitude about when the patient would like clinicians to broach the
subject of what is involved when turning of the deﬁbrillating shocks, N = 3067.
Never wishes to have such a discussion,
Omnibus p value b .001
B P
value
Odds
ratio
95% CI
Symptoms of depression −.031 .850 .969 .701–1.340
Symptoms of anxiety −.435 .001 .647 .501–.835
Quality-of-life score .207 .342 1.230 .803–1.884
Male −.098 .315 .906 .748–1.098
Age b 65 years (vs. ≥65 years) .230 .006 1.259 1.067–1.486
≤9 years of education (vs. N9 years) −.074 .385 .929 .786–1.097
Time since implantation of ICD, years .002 .870 1.002 .973–1.033
CRT-D (vs. ICD only) −.069 .481 .933 .770–1.131
Secondary prevention (vs. primary) −.036 .692 .965 .808–1.151
Received ICD shocks .422 b .001 1.525 1.285–1.810
Had prior generator replacement .154 .239 1.166 .903–1.506
Legend: CI = conﬁdence intervals; CRT-D = Cardiac Resynchronization Therapy-
Deﬁbrillator; ICD = Implantable Cardioverter Deﬁbrillator.
Table 5
Prevalence of attitudes regarding ICD battery replacement even if no shocks have been delivered N = 3067 *.
Socio-demographics Age** Sex Education level **
b65 years
N (%)
≥65 years
N (%)
Male
N (%)
Female
N (%)
≤9 years
N (%)
N9 years
N (%)
Yes 861 (81.8) 1520 (78.3) 1893 (79.6) 488 (79.1) 749 (77.0) 1613 (80.7)
No 33 (3.1) *** 108 (5.5) 114 (4.8) 27 (4.4) 62 (6.4) *** 78 (3.9)
Can't take a stand 159 (15.1) 314 (16.2) 371 (15.6) 102 (16.5) 161 (16.6) 308 (15.4)
Implantation indication and device ICD indication CRT
Primary Secondary Yes No
Yes 858 (79.6) 1522 (79.4) 556 (80.1) 1821 (79.3)
No 40 (3.7) 101 (5.3) 26 (3.8) 115 (5.0)
Can't take a stand 180 (16.7) 293 (15.3) 112 (16.1) 361 (15.7)
Post-implantation experiences Time since implant ** Shock experience Generator replacement **
≤5 years N5 years Shock No shock Yes No
Yes 1639 (77.7) 742 (83.8) 814 (79.0) 1546 (80.1) 633 (83.5) 1748 (78.1)
No 100 (4.7) 41 (4.7) 56 (5.4) 82 (4.2) 41 (5.4) 100 (4.5)
Can't take a stand 371 (17.6) *** 102 (11.5) *** 161 (15.6) 302 (15.7) 84 (11.1) *** 389 (17.4) ***
Psychological factors Symptoms of anxiety Symptoms of depression**
Yes No Yes No
Yes 362 (76.7) 1982 (80.2) 187 (73.6) 2158 (80.1)
No 24 (5.1) 116 (4.7) 21 (8.3) *** 118 (4.4)
Can't take a stand 86 (18.2) 374 (15.1) 46 (18.1) 419 (15.5)
End-of-life discussions with ICD team Battery replacement ** Illness trajectory ** Deactivation
Yes No Yes No Yes No
Yes 1080 (83.9) 1283 (76.2) 909 (82.0) 1445 (78.0) 337 (78.7) 2023 (79.7)
No 62 (4.8) 77 (4.6) 50 (4.5) 89 (4.8) 26 (6.1) 111 (4.4)
Can't take a stand 145 (11.3) *** 324 (19.2) *** 149 (13.5) *** 318 (17.2) 65 (15.2) 404 (15.9)
Legend: * Of the total, yes, n = 2381 (79.5%); no, n = 141 (4.7%); can't take a stand, n = 473 (15.4%); ** = overall chi-square signiﬁcant at p b .05; *** = post-hoc examination of the stan-
dardized residuals was used to determine which cell or cells contributed to the signiﬁcant difference and those cells marked with a *** exceeded the critical value associated with p b .05.
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gender (β.108, p = .001), depressive symptoms (β.122, p = .002),
and experiences with the ICD (β. 077, p = .036) were signiﬁcant
predictors. Women, those without depressive symptoms, and those
with worse ICD experiences were more indecisive.
4. Discussion
In our nationwide survey of more than 3000 patients with ICDs, we
found that only a minority had discussed the implications of generator
replacement at battery-end-of-service or had discussed potential ICD
deactivation at the end-of-life. Moreover, many patients were unable
to foresee what they might prefer to do with their ICD in an end-of-
life situation. These ﬁndings suggest a number of possibilities with
regard to the recommendations offered in current expert consensus
statements about managing ICD patients [1,2], the effectiveness of
such statements, and whether they are being followed.
As Kramer and colleagues [19] recently discussed; is it time for a new
approach to ICD replacements? They point to the fact that the appropri-
ateness of initial device placement has been closely scrutinized, but
there has been little consideration as to what happens in the years
after implantation when ICD battery drains sufﬁciently to require re-
placement. They suggest that the guidelines for initial ICD implantation
[20] should be followed when making recommendations to patients
regarding replacement, i.e., the patient should be expected to survive
for at least one year with a reasonable quality-of-life. When we asked
our participants, however, the majority stated that they would like to
replace the battery, even if no shock therapy had been delivered, even
if they had reached a very advanced age, or even if they were seriously
ill with a terminal disease like cancer. This implies the importance ofmaking battery replacement a more deliberative process where patient
preferences, past experiences, and advance care planning should be ex-
plicitly included in decision making together with a comprehensive
medical evaluation [19].
We found a strikingly low rate of discussions about the possibility of
deactivating the device near the end-of-life suggesting a lack of concor-
dancewith the current consensus statements. Before implanting an ICD,
clinicians should explain that these devices may avert sudden cardiac
death, but that later in life the beneﬁts versus the negatives of the
ICDs should be re-evaluated. For example, if the patient is stricken
with a fatal illness, the physician should, in accordancewith existing ex-
pert consensus statements [1,2], explain that death from an arrhythmia
may be a bettermode of dying than that the patient faces from their ter-
minal condition. The statements also suggest that the physician should
explain that repeated ICD shocks may be distressing to the patient and
family as death nears. However – and in contrast to the advice given
by experts in the consensus statements [1,2] – as many as 40% of our
participants stated that they never wanted the physician to initiate a
discussion about deactivation in an anticipated end-of-life situation
and those in favor of a discussion, preferred it to take place during the
last days in life. Others have also reported that patients prefer to discuss
deactivation only late in their illness trajectory [6,7]. This highlights the
importance that the opinion of patients should be considered at the
time of initiating a discussion on terminal conditions or delivery these
types of documents. When attempting to deﬁne sub-groups of patients
who had participated in discussions about withdrawal of ICD therapy,
we found that anxious patients, patients younger than 65 years, and
those who had received ICD shocks and prior battery replacement
were more likely to have had such a discussion. These ﬁndings could
be explained by the fact that relative youth may be associated with a
Table 6
Prevalence of attitudes regarding ICD battery replacement even if at an advanced age, N = 3067*.
Socio-demographics Age ** Sex ** Education level
b65 years
N (%)
≥65 years
N (%)
Male
N (%)
Female
N (%)
≤9 years
N (%)
N9 years
N (%)
Yes 609 (57.9) 1267 (65.1) 1571 (66.1)*** 305 (49.3) *** 620 (63.3) 1240 (62.3)
No 131 (12.5) *** 174 (8.9) 207 (8.7) *** 98 (15.8) *** 108 (11.0) 196 (9.8)
Can't take a stand 311 (29.6) 504 (25.9) 599 (25.2) 216 (34.9) *** 252 (25.7) 555 (27.9)
Implantation indication and device ICD indication CRT **
Primary Secondary Yes No
Yes 670 (62.2) 1205 (62.8) 459 (65.8) 1414 (61.6)
No 108 (10.0) 197 (10.3) 55 (7.9) 250 (10.9)
Can't take a stand 300 (27.8) 515 (26.9) 183 (26.3) 631 (27.5)
Post-implantation experiences Time since implant Shock experience ** Generator replacement
≤5 years N5 years Shock No shock Yes No
Yes 1308 (62.0) 568 (64.2) 685 (66.3) 1175 (60.9) 477 (62.9) 1399 (62.5)
No 210 (9.9) 95 (10.7) 95 (9.2) 204 (10.6) 89 (11.7) 216 (9.7)
Can't take a stand 593 (28.1) 222 (25.1) 253 (24.5) 549 (28.5) 192 (25.4) 623 (27.8)
Psychological factors Symptoms of anxiety Symptoms of depression
Yes No Yes No
Yes 276 (58.9) 1568 (63.3) 148 (58.3) 1698 (63.0)
No 56 (11.9) 243 (9.8) 34 (13.4) 265 (9.8)
Can't take a stand 137 (29.2) 665 (26.9) 72 (28.3) 734 (27.2)
End of life discussions with ICD team Battery replacement *** Illness trajectory Deactivation
Yes No Yes No Yes No
Yes 865 (67.3) *** 999 (59.3) 723 (65.3) 1135 (61.1) 282 (66.0) 1578 (62.1)
No 121 (9.4) 179 (10.6) 110 (9.9) 191 (10.3) 49 (11.5) 252 (9.9)
Can't take a stand 299 (23.3) *** 508 (30.1) *** 274 (24.8) 530 (28.6) 96 (22.5) 712 (28.0)
Legend: * Of the total, yes, n = 1876 (62.6%); no, n = 305 (10.2%); can't take a stand, n = 815 (27.2%); ** = overall chi-square signiﬁcant at p b .05; *** = post-hoc examination of the
standardized residuals was used to determine which cell or cells contributed to the signiﬁcant difference and those cells marked with a *** exceeded the critical value associated with
p b .05.
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and the experience of having an arrhythmia that results in ICD shocks
leads to more consultations and thus more opportunities to have this
conversation. Anxiety is a common factor in promoting discussions as
anxious patients attempt to resolve their anxiety by gaining more
information.
We also found that themajority of theparticipants had not discussed
their illness trajectory with their physician or a family member. While
advanced directives are considered an essential part of care for the
ICD population, this was not a reality in our study where only 7% had
expressed their preferable wishes, verbally or in writing, to their family.
This is in line with Conelius [13] who found that participants were
uncomfortable discussing advanced directives with their families. It is
reasonable to assume that these preferences emanate from a wish to
postpone decisions and even forget about the real reason for having
an ICD. This desire by patients to avoid such discussions is in conﬂict
with existing consensus statements [1,2] that recommend discussions
of deactivation when the patient's clinical status worsens. Statements
are based on the knowledge that ICD shocks are painful and psycholog-
ically stressful as well as futile in terminal illness. Expert recommenda-
tions, however, assume that patients are willing and prepared to have a
discussion about their illness and end-of-life issues while in reality,
most are not and most could not foresee if they would prefer to with-
draw ICD therapy even if dying froma terminal illness. Ourﬁndings sug-
gest that clinicians may need to concentrate on better preparing
patients to have discussions about the end-of-life and this need should
be acknowledged in future guidelines. It also may be that clinicians
need further education about how to appropriately engage in end-of-
life discussions with ICD patients [21]. These factors are importantbecause ICD patients and their families cannot make appropriate deci-
sions without a clear understanding of available options, which may
lead to a prolonged and uncomfortable death [22].
Although a large number of our patients could not take a stand about
ICD deactivation if confronted with a terminal illness, of those who
could take a stand in advance, the majority stated that they would pre-
fer deactivation. Every ﬁfth patient, however, believed that they would
like the shock therapies to remain active. These results support ﬁndings
from previous, small scale studies demonstrating that the majority of
patients prefer to keep their ICD active [5,7,10] while some favor device
deactivation at end-of-life [6,9]. Together these data demonstrate that
ICD recipients form a heterogeneous group.
What clinical conclusions can be drawn from these results? One of
the most striking ﬁnding in our study is the unwillingness in certain
groups to have a discussion about deactivation. This, however, cannot
be taken as a pretext for failing to provide patients with their options
in an end-of-life situation. Rather this ﬁnding highlights the importance
of being aware of patients' ambivalence, understanding that preferences
are unique among individuals, and that patients with different charac-
teristics have different needs. Thus, the timing of every discussion
with the patient must be decided on an individual basis. This is particu-
larly important because illness trajectory and terminal deterioration of
health often is unpredictable [23–27]. However, continuity of care for
patients with an ICD in the end-of-life is complex [28]. One reason for
this is the lack of collaboration among healthcare providers which
may lead to fragmented care for the ICD patient [22] and this should
also be acknowledged in future guidelines.
Because previous research [29] has suggested that patients may be
too anxious when diagnosed and thus are not receptive to having
Table 7
Prevalence of attitudes regarding ICD battery replacement even if seriously ill with another disease, N = 3067 *.
Socio-demographics Age Sex ** Education level
b65 years
N (%)
≥65 years
N (%)
Male
N (%)
Female
N (%)
≤9 years
N (%)
N9 years
N (%)
Yes 564 (53.7) 1070 (55.1) 1354 (57.0) 280 (45.3) *** 542 (55.5) 1079 (54.1)
No 123 (11.7) 206 (10.6) 240 (10.1) 89 (14.4) *** 120 (12.3) 208 (10.5)
Can't take a stand 364 (34.6) 667 (34.3) 782 (32.9) 249 (40.3) *** 315 (32.2) 706 (35.4)
Implantation indication and device ICD indication CRT**
Primary Secondary Yes No
Yes 574 (53.4) 1060 (55.3) 400 (57.5) 1231 (53.7)
No 122 (11.3) 207 (10.8) 59 (8.5) *** 270 (11.8)
Can't take a stand 380 (35.3) 650 (33.9) 237 (34.0) 793 (34.5)
Post-implantation experiences Time since implant Shock experience Generator replacement
≤5 years N5 years Shock No shock Yes No
Yes 1128 (53.4) 506 (57.3) 584 (56.7) 1031 (53.4) 420 (55.6) 1214 (54.2)
No 227 (10.8) 102 (11.6) 123 (11.9) 200 (10.4) 88 (11.6) 241 (10.8)
Can't take a stand 756 (35.8) 275 (31.1) 323 (31.4) 698 (36.2) 248 (32.8) 783 (35.0)
Psychological factors Symptoms of anxiety Symptoms of depression
Yes No Yes No
Yes 247 (52.3) 1357 (54.9) 134 (52.7) 1475 (54.8)
No 56 (11.9) 270 (10.9) 37 (14.6) 283 (10.5)
Can't take a stand 169 (35.8) 845 (34.2) 83 (32.7) 935 (34.7)
End of life discussions with ICD team Battery replacement Illness trajectory ** Deactivation
Yes No Yes No Yes No
Yes 748 (58.3) 874 (51.8) 639 (57.7) 977 (52.7) 234 (54.8) 1384 (54.5)
No 133 (10.4) 193 (11.4) 108 (9.8) *** 216 (11.6) 63 (14.8) 261 (10.3)
Can't take a stand 401 (31.3) 621 (36.8) 360 (32.5) 661 (35.7) 130 (30.4) 895 (35.2)
Legend: * Of the total, yes, n = 1634 (54.6%); no, n = 329 (11%); can't take a stand, n = 1031 (34.4%); ** = overall chi-square signiﬁcant at p b .05; *** = post-hoc examination of the
standardized residuals was used to determine which cell or cells contributed to the signiﬁcant difference and those cells marked with a *** exceeded the critical value associated with
p b .05.
29I. Thylén et al. / IJC Heart & Vessels 1 (2013) 22–31such discussions at that stage, perhaps end-of-life issues should be
discussed at follow-up visits but not pre-implantation as suggested in
expert consensus statements [1,2]. Further supporting this suggestion
is the ﬁnding that many patients change their minds regarding deacti-
vation over the course of their illness [29]. Half of our participants, how-
ever, favored receiving information about deactivation while in the
hospital. Together this and related data suggest that frequent attempts
at discussion starting from the ﬁrst consultation prior to implantation –
as suggested in consensus statements – and continuing on through the
post-implantation period and as patients' conditions change, seem rea-
sonable and is also in linewithDunbar and colleagues' recommendations
about educational and psychological interventions to improve ICD
recipient outcomes [21]. When such discussions are done with sensitiv-
ity to patient preferences, they likely will not be viewed as offensive, but
presumed to be in every patient's best interest.
It is also possible that resistance to discussing deactivation partly
can be explained by lack of actual knowledge and true understanding
of the ICD and its functions. Many patients do not understand the
speciﬁcs of their device with regard to their medical condi-
tion [13,30,31]. By openly discussing the illness trajectory and option
of deactivating an ICD, after providing patients with sufﬁcient
knowledge to process these discussions, clinicians encourage shared
decision making and provide patients control over their healthcare
choices. A better understanding of patients' actual insights in their
disease and the role of the ICD could be reached with the help of spe-
ciﬁc questionnaires in addition to discussions throughout the illness
trajectory and make it possible to design an individual scheme for
education and support. This way to optimize follow-up and patient
support has to be further investigated, however.4.1. Limitations
This study is limited by the fact that the most psychologically dis-
tressed patients and those with poor physical and mental functioning
may not have agreed to participate. Although there were no differences
in age, gender, time since implantation and indication for the ICD
between those who participated in the study and those who did not,
we were unable to collect further data from those who did not partici-
pate. Furthermore, persons responding may want to be perceived as
“good patients” by not reporting problems, although our consent pro-
cess insured that patients were informed that the questionnaires
would be made anonymous before data entry. Only one data collection
point was used, and longitudinal study of a cohort of patients would be
helpful in understanding the process of adjustment, experiences, and
attitudes and knowledge about the ICD over time. Further, more than
60% of patients had ICD implanted as secondary prevention. This is a
relatively high rate for current practice which could be seen as a limita-
tion. Lastly, this was an observational study and thuswe can only report
association rather than infer causation.
5. Conclusions
In this study, we examined experiences of discussion, and attitudes
about end-of-life among patients with an ICD while controlling for
levels of psychological distress and quality-of-life. The vast majority of
the patients had not discussed deactivation with the ICD team and a
large minority of younger and healthier patients did not want this
discussion at all. Many patients, above all women, those with recent
implant and those with good quality-of-life or those with worse ICD
Table 8
Prevalence of attitudes regarding the maintenance of ICD therapy in the context of terminal illness (keep shocks even if dying of cancer or other serious disease), N = 3067 *.
Socio-demographics Age Sex ** Education level
b65 years
N (%)
≥65 years
N (%)
Male
N (%)
Female
N (%)
≤9 years
N (%)
N9 years
N (%)
Yes 216 (20.5) 455 (23.4) 576 (24.3) 95 (15.3) *** 241 (24.7) 424 (21.2)
No 433 (41.1) 719 (37.1) 882 (37.2) 270 (43.5) *** 362 (37.1) 783 (39.3)
Can't take a stand 404 (38.4) 766 (39.5) 914 (38.5) 256 (41.2) 372 (38.2) 787 (39.5)
Implantation indication and device ICD indication CRT **
Primary Secondary Yes No
Yes 256 (23.8) 415 (21.7) 184 (26.5) *** 486 (21.2)
No 413 (38.4) 738 (38.5) 244 (35.1) 906 (39.5)
Can't take a stand 407 (37.8) 763 (39.8) 267 (38.4) 902 (39.3)
Post-implantation experiences Time since implant Shock experience Generator replacement **
≤5 years N5 years Shock No shock Yes No
Yes 485 (23.0) 186 (21.1) 243 (23.6) 419 (21.7) 138 (18.2) *** 533 (23.8)
No 796 (37.7) 356 (40.3) 395 (38.3) 742 (38.5) 309 (40.8) 843 (37.7)
Can't take a stand 829 (39.3) 341 (38.6) 392 (38.1) 767 (39.8) 310 (41.0) 860 (38.5)
Psychological factors Symptoms of anxiety Symptoms of depression
Yes No Yes No
Yes 111 (23.6) 546 (22.1) 55 (21.7) 605 (22.4)
No 174 (37.0) 961 (38.9) 106 (41.7) 1028 (38.2)
Can't take a stand 185(39.4) 964 (39.0) 93 (36.6) 1061 (39.4)
End-of-life discussions with ICD team Battery replacement Illness trajectory Deactivation **
Yes No Yes No Yes No
Yes 292 (22.8) 374 (22.2) 267 (24.1) 396 (21.4) 113 (26.3) 549 (21.6)
No 508 (39.6) 632 (37.6) 422 (38.1) 719 (38.8) 174 (40.4) 966 (38.1)
Can't take a stand 483 (37.6) 677 (40.2) 419 (37.8) 738 (39.8) 143 (33.3) *** 1021 (40.3)
Legend: * Of the total, Yes, n = 671 (22.4%);No, n = 1152 (38.5%); Can't take a stand, n = 1170 (39.1%); ** = overall chi-square signiﬁcant at p b .05; *** = post-hoc examination of the
standardized residuals was used to determine which cell or cells contributed to the signiﬁcant difference and those cells marked with a *** exceeded the critical value associated with
p b .05.
30 I. Thylén et al. / IJC Heart & Vessels 1 (2013) 22–31experiences were indecisive about deactivation or ICD replacement.
Irrespective of shock experiences, those who could take a stand regard-
ing deactivation chose to keep shock therapies active inmany cases. The
divergence in attitudes we found in our study reﬂect the heterogeneity
and ambivalence of a large group of ICD recipients in a stable medical
condition where psychological states, needs and experiences vary and
the conclusion is that “one model” does not ﬁt all.
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